COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB AMONG PRETERM INFANTS COVERED BY MEDICAID IN THE UNITED STATES

被引：1
|
作者：
Weiner, L. B. [1 ]
Polak, M. J. [2 ]
Masaquel, A. [3 ]
Mahadevia, P. J. [3 ]
机构：
[1] Upstate Med Univ, Syracuse, NY USA
[2] W Virginia Univ, Sch Med, Morgantown, WV 26506 USA
[3] MedImmune, Gaithersburg, MD USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.655
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A118 / A118
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden
    Neovius, Kristian
    Buesch, Katharina
    Sandstrom, Kristina
    Neovius, Martin
    ACTA PAEDIATRICA, 2011, 100 (10) : 1306 - 1314
  • [2] Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants
    Joffe, S
    Ray, GT
    Escobar, GJ
    Black, SB
    Lieu, TA
    PEDIATRICS, 1999, 104 (03) : 419 - 427
  • [3] COST-EFFECTIVENESS OF PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) WITH PALIVIZUMAB IN PRETERM INFANTS IN COLOMBIA
    Rosselli, D.
    Rueda, J. D.
    Ruiz, J. G.
    VALUE IN HEALTH, 2013, 16 (03) : A75 - A75
  • [4] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Reeve, Carole A.
    Whitehall, John S.
    Buettner, Petra G.
    Norton, Robert
    Reeve, David M.
    Francis, Fleur
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (05) : 253 - 258
  • [5] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Mahadevia, Parthiv J.
    Malinoski, Frank J.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (05): : 519 - 520
  • [6] Cost-effectiveness of respiratory syncytial virus (RSV) prophylaxis among preterm infants in Poland
    Kowalik, E
    Jakubczyk, MK
    Niewada, MP
    Kamiñski, B
    VALUE IN HEALTH, 2003, 6 (06) : 758 - 759
  • [7] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab - Reply
    Sorbero, Melony E. S.
    ElHassan, Nahed O.
    Hall, Caroline B.
    Stevens, Timothy P.
    Dick, Andrew W.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (05): : 520 - 520
  • [8] Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks ' gestation in the United States
    Yu, Tianzhou
    Padula, William, V
    Yieh, Leah
    Gong, Cynthia L.
    PEDIATRICS AND NEONATOLOGY, 2024, 65 (02): : 152 - 158
  • [9] Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis
    Lolfand, JH
    Touch, SM
    O'Connor, JP
    Chatterton, ML
    Moxey, ED
    Paddock, LE
    Nash, DB
    Desai, SA
    CLINICAL THERAPEUTICS, 2000, 22 (11) : 1357 - 1369
  • [10] COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY
    Hampp, C.
    Kauf, T. L.
    Saidi, A.
    Winterstein, A. G.
    VALUE IN HEALTH, 2009, 12 (07) : A301 - A302
12345